Type 2 diabetes (T2D), one of most prevalent chronic diseases in developed societies, is initiated by the induction of glucose intolerance, a prediabetic state of hyperglycemia that is frequently caused by insulin resistance in peripheral tissues such as liver and muscles. Over the past few decades, research has extensively focused on the role of peripheral tissues in the development of glucose intolerance and insulin resistance in order to decipher the underlying mechanisms of these conditions. And, indeed, much insight has been elucidated [1] [2] [3] [4] .
Type 2 diabetes (T2D), one of most prevalent chronic diseases in developed societies, is initiated by the induction of glucose intolerance, a prediabetic state of hyperglycemia that is frequently caused by insulin resistance in peripheral tissues such as liver and muscles. Over the past few decades, research has extensively focused on the role of peripheral tissues in the development of glucose intolerance and insulin resistance in order to decipher the underlying mechanisms of these conditions. And, indeed, much insight has been elucidated [1] [2] [3] [4] .
Despite this progress, there is still a critical lack of successful solutions for stopping the T2D epidemic, perhaps implying that additional mechanisms remain to be unveiled. Notably, recent research advances in neuroendocrinology have suggested that the central nervous system (CNS), in particular the hypothalamus, has appreciable effects on glucose homeostasis [5] [6] [7] [8] [9] . Furthermore, these effects can be dissociated from the role of the hypothalamus in regulating body weight, which also has been extensively studied over the past decades 10, 11 . However, it remains unexplored whether the brain has a distinct role in the development of T2D by certain prodiabetic etiologies, such as obesity and aging. Of note, recent studies have demonstrated that hypothalamic inflammation occurs not only in obesity [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] but also in aging [23] [24] [25] . In general, hypothalamic inflammation in obesity or aging is attributed to an atypical activation of proinflammatory nuclear factor-κB (NF-κB) [12] [13] [14] [18] [19] [20] [23] [24] [25] [26] [27] ; yet, the causes and characteristics of this atypical inflammation are still poorly defined.
In this work, we found that the brain can directly induce a prediabetic glucose disorder through a centrally mediated effect of excess TGF-β, a cytokine that is often overproduced during inflammation and that has mixed biological functions 28 . Mechanistically, central TGF-β excess induces hypothalamic RNA stress granules to enhance decay of Nfkbia mRNA, which encodes IκBα. The resulting loss of IκBα causes activation of hypothalamic NF-κB, which in turn induces molecular inflammatory changes. Together these results suggest a hypothalamic inflammatory basis for the contribution of obesity and aging to the development of T2D.
RESULTS
Hypothalamic TGF-b excess in pro-T2D etiological conditions As obesity and aging are associated with atypical hypothalamic inflammation, we used mice under a variety of appropriate conditions to comparatively analyze the hypothalamic expression levels of genes that are closely associated with inflammation but are not strongly proinflammatory. In particular, we examined the hypothalamus from high-fat diet (HFD)-fed versus normal chow-fed mice and middleaged versus young mice, as well as mice fed ad libitum versus those that were calorie restricted. We observed that hypothalamic TGF-β1 levels were different across these conditions. Tgfb1 mRNA levels were higher in HFD-fed mice as well as aged mice compared to their respective controls. By examining caloric restriction, which is known to counteract the effects of not only obesity but also aging, we found that 2-month caloric restriction was sufficient to lower hypothalamic Tgfb1 mRNA levels in aged mice (Supplementary Table 1) .
We further examined additional time points of HFD feeding or aging and found that both short-term HFD feeding and early-stage aging were associated with higher Tgfb1 mRNA levels compared to a r t i c l e s 1 0 0 2 VOLUME 20 | NUMBER 9 | SEPTEMBER 2014 nature medicine normal chow-fed and young mice, respectively (Fig. 1a,b) . These mRNA changes were associated with higher protein levels, as the TGF-β content of the cerebrospinal fluid (CSF) of both HFD-fed mice and aged mice was higher than that of their respective matched controls (Fig. 1c,d ). In addition to TGF-β1, which is the predominant TGF-β isoform 29 , we analyzed TGF-β2 and TGF-β3 and found that the hypothalamic mRNA levels of these two isoforms were also higher in HFD-fed mice or aged mice compared to normal chow-fed and young mice, respectively ( Supplementary Fig. 1a-d) . In light of this finding, we decided to study whether excess central TGF-β might have effects on metabolic physiology in mice.
Excess central TGF-b causes metabolic dysfunction
To study the metabolic effects of excess TGF-β in the brain, we first used a pharmacological approach to deliver TGF-β into the hypothalamic third ventricle of normal C57BL/6 mice via preimplanted cannula. To optimize the dosage, we injected different doses of TGF-β1 (0, 0.5, 1.0 and 4.0 ng) and measured TGF-β1 concentrations in the CSF at various time points after injection. We found that the increase of CSF TGF-β1 concentration peaked at 15 min after injection in a dose-dependent manner and that at 60 min after injection, TGF-β1 concentration in the CSF declined to levels roughly twofold higher than the basal concentration ( Supplementary  Fig. 2a) . None of these doses significantly increased the blood TGF-β1 concentration (Supplementary Fig. 2b ). On the basis of these findings, we gave overnight-fasted mice intra-third-ventricle injections of TGF-β1 in these doses, with one injection at night after food was removed and the second injection the following morning 4 h before a glucose tolerance test (GTT). TGF-β1 treatment at each dose led to glucose intolerance, and the effect from 4 ng TGF-β was strongest (Fig. 1e) .
Following this observation, we further studied whether impaired glucose tolerance in these mice was a result of insulin resistance. Thus we performed an insulin tolerance test (ITT), which showed that the ability of insulin to lower blood glucose was significantly dampened in TGF-β1-injected mice compared to vehicle-injected mice (Fig. 1f) .
In contrast to these effects on blood glucose, the same protocol of TGF-β1 treatment did not affect food intake or body weight for 24 h after injection ( Supplementary Fig. 2c,d ). In sum, we found that pharmacological delivery of excess TGF-β directly to the brain can acutely cause prediabetic symptoms, including glucose intolerance and insulin resistance.
As blood glucose levels are determined by a balance between glucose production (typically in the liver) and glucose utilization, we used a hyperinsulinemic-euglycemic clamp to analyze whether any of these metabolic processes were perturbed in states of central TGF-β excess. We implanted a catheter into the jugular vein and also a cannula into the hypothalamic third ventricle of C57BL/6 mice. Following surgical recovery, we injected overnight-fasted mice with TGF-β1 (4 ng) using the same protocol as described in Figure 1e and subjected them to the clamp procedure. During the clamp period, blood glucose concentrations were maintained at approximately 120-130 mg dl −1 , with steady insulin infusion (4 mU per kg body weight per min) together with various rates of 20% glucose infusion to maintain euglycemia (Supplementary Fig. 3a ). Glucose infusion rates in TGF-β1-injected mice were significantly lower than those in vehicleinjected mice following the first 20 min of clamp ( Supplementary  Fig. 3a) , suggesting the former were insulin resistant. Although the basal blood insulin concentrations in TGF-β1-injected mice were higher than those in controls, further indicating insulin resistance, constant insulin infusion in the clamp elevated the blood insulin concentrations of these mice and controls to similar levels ( Supplementary  Fig. 3b ). The calculated data revealed that as a response to similarly increased insulin concentrations, the glucose infusion rate in TGF-β1-injected mice was on average 80% lower than that of vehicleinjected mice (Fig. 1g) . This change was consistent with the data from the GTTs, as both showed that these mice were glucose intolerant (Fig. 1e) . The rates of glucose disposal were, however, similar between TGF-β1-injected and vehicle-injected mice (Fig. 1h) , suggesting that tissue glucose uptake was not significantly altered by excess levels of central TGF-β. In contrast, even under basal conditions, hepatic glucose production in TGF-β1-treated mice was higher compared (e-j) C57BL/6 mice injected with artificial CSF as vehicle (Veh) or TGF-β1 at the indicated doses (e) or 4 ng (f-j) and examined by GTTs (e), ITTs (f) or by insulin clamp (g-j). Bar graphs (e,f) showing the calculated values for area under curve (AUC) during the 120-min test course of the GTTs (mg dl −1 × 120 min, ×10 3 ) and ITTs (% of control). Glucose infusion rate (GIR) (g), rate of glucose disposal (Rd) (h) and hepatic glucose production (GP) (i,j) in the clamp experiment. Two-tailed Student's t-test was used for comparisons between two groups. *P < 0.05, **P < 0.01, ***P < 0.001; n = 4 (a-d), n = 9 for vehicle-treated group, n = 8 for 0.5-ng TGF-β1-treated group, n = 7 for 1-ng TGF-β1-and 4-ng TGF-β1-treated groups (e,f) and n = 5 (g-j) mice per group. Error bars reflect mean ± s.e.m. AU = arbitrary units. npg to control mice (Fig. 1i) , and during the clamp, although insulin infusion suppressed hepatic glucose production in control mice by ~75%, it failed to do so in TGF-β1-treated mice (Fig. 1j) . Blood glucagon concentrations were similar between TGF-β1-treated mice and controls (Supplementary Fig. 3c ). Together, these results suggest that excess central TGF-β induces metabolic dysfunction and that a brainliver axis mediates these effects.
Astrocytes are a key source of excess central TGF-b Following our pharmacological studies, we developed a genetic mouse model to induce excess brain TGF-β1 using a transgenic mouse line containing cytomegalovirus promoter (CMV)-flox-stop-flox-Tgfb1 inserted into the genome 30 . As established 30 , the floxed fragment in this transgenic line prevents expression of transgenic TGF-β1, and introduction of Cre leads to the removal of the floxed fragment and therefore TGF-β1 overexpression in Cre-positive cells. Because we detected TGF-β1 mostly in astrocytes (rather than in neurons) in C57BL/6 mice, we generated transgenic mice with astrocyte-specific TGF-β1 overexpression by breeding CMV-flox-stop-flox-Tgfb1 mice with GFAP-Cre mice (which express Cre in the brain predominantly in astrocytes). From these crosses, we obtained the compound mice, termed GFAP-Tgfb1 tg/− mice, and Tgfb1 tg/− littermate controls. Hypothalamic immunostaining images showed that although TGF-β1 was present in the astrocytes of control mice, its expression levels were specifically higher in the astrocytes of GFAP-Tgfb1 tg/− mice (Fig. 2a,b) .
We maintained GFAP-Tgfb1 tg/− mice and littermate controls under normal chow feeding and confirmed that they had normal development as well as normal food intake and body weight (Fig. 2c,d) . In contrast, compared to control mice with a normal glucose profile, normal chow-fed GFAP-Tgfb1 tg/− mice were glucose intolerant (Fig. 2e) , and even fasting blood glucose levels of these mice tended to be higher. ITTs revealed that GFAP-Tgfb1 tg/− mice were severely insulin intolerant (Fig. 2f) . Taken together, these results suggest that GFAP-Tgfb1 tg/− mice developed glucose intolerance and insulin resistance independently of a change in body weight.
In parallel with the TGF-β1 gain-of-function model, we studied how an inhibition of brain-derived TGF-β could affect blood glucose levels in physiology or disease. Because astrocytes are an important source of excess central TGF-β and the consequent metabolic dysfunction (Fig. 2) , we continued to target astrocytes. To do so, we bred Tgfb1 flox/flox mice with GFAP-Cre mice, which resulted in mice with astrocytespecific Tgfb1 knockout (GFAP-Tgfb1 flox/flox mice) and Tgfb1 flox/flox littermate controls. When maintained under normal chow feeding, we found that GFAP-Tgfb1 flox/flox mice and control mice were comparable in terms of development, food intake, body weight, glucose tolerance and insulin tolerance ( Supplementary Fig. 4a-d ).
We then employed HFD feeding to induce glucose and insulin intolerance and test how these disorders were affected by astrocytic TGF-β deficiency. To better appreciate a primary effect of TGF-β deficiency on changes in metabolic parameters independent of a prominent change in adiposity, we used HFD feeding for a relatively short duration (3 weeks) as this allows for sufficient induction of glucose intolerance and insulin resistance but without the development of profound obesity and with limited complex peripheral mechanisms. Under these conditions, control mice developed impairments in glucose tolerance and insulin resistance; in contrast, GFAP-Tgfb1 flox/flox mice were resistant to both of these changes (Fig. 3a,b) . However, under this 3-week HFD regime, food intake and body weight levels in GFAP-Tgfb1 flox/flox and control mice were still comparable ( Supplementary Fig. 4e,f) , although we did not study whether chronic obesity development via long-term HFD feeding could be affected in this genetic model. Hence, given our results in astrocytespecific TGF-β1 loss-of-function as well as gain-of-function models, we conclude that astrocytes play a part in the metabolic dysfunction caused by excess abundance of central TGF-β.
POMC neurons mediate the metabolic effects of excess TGF-b
We subsequently studied whether expression levels of hypothalamic neuropeptide genes are changed by excess central TGF-β. Of note, we found that proopiomelanocortin (Pomc) mRNA levels in the hypothalamus of TGF-β1-injected mice were lower compared to levels in controls ( Supplementary Fig. 5a ), a finding that agrees with the literature 31 . In light of this finding, we studied whether POMC neurons could be crucial for the metabolic effects of excess brain TGF-β. To do so, we targeted TGF-β receptor-2 (TGFβR2) specifically in POMC neurons, as TGFβR2 is required for TGF-β signaling and, experimentally, TGFβR2 knockout has been shown to inhibit TGF-β signaling 32 . We genetically deleted These mice were maintained on normal chow feeding or 3-week HFD feeding. We found that chow-fed POMC-Tgfbr2 flox/flox mice and controls demonstrated normal levels in food intake, body weight and glucose and insulin tolerance ( Supplementary Fig. 5b-e) . However, under the condition of 3-week HFD feeding, although food intake and body weight of these mice were still comparable ( Supplementary Fig. 5f,g ), both HFDinduced glucose intolerance and insulin insensitivity were markedly lower in POMC-Tgfbr2 flox/flox mice compared to Tgfbr2 flox/flox littermate controls (Fig. 3c,d ). These results suggest that TGF-β signaling in POMC neurons has a role in the metabolic effects of excess central TGF-β excess. However, considering that TGF-β signaling is present in other hypothalamic regions 33 and POMC-Cre can target other types of neurons during the developmental stage 34 , the cellular mechanism by which excess central TGF-β affects metabolism may involve additional hypothalamic or extrahypothalamic neuron populations.
NF-kB activation by TGF-b contributes to metabolic disease TGF-β has often been found to have an anti-inflammatory role in immune responses, but, depending on the physiological context or the pathological condition, TGF-β can also be proinflammatory 28 although this function is atypical and many details of its proinflammatory actions are still unclear. Here, because NF-κB has been known to mediate hypothalamic nonclassical inflammation in obesity or aging [12] [13] [14] [18] [19] [20] [23] [24] [25] [26] [27] , we analyzed whether NF-κB signaling components were differentially expressed in the hypothalamus of mice with third-ventricle injection of TGF-β versus that of mice injected with vehicle. Although many of these components had similar protein levels between the two groups, TGF-β1 injection led to a significant reduction in IκBα protein levels (Fig. 4a) . Because IκBα is the canonical and specific inhibitor of NF-κB, this result suggested that hypothalamic NF-κB was activated in TGF-β1-injected mice, and our subsequent experiments confirmed this. First, as IκBα loss is the specific step that immediately liberates cytoplasmic NF-κB for nuclear translocation and the NF-κB subunit RelA subsequently undergoes phosphorylation, we measured hypothalamic RelA phosphorylation in mice injected with TGF-β1 or vehicle and found that it was higher in the former group versus the control group (Fig. 4a) . Second, we evaluated whether TGF-β1-triggered NF-κB activation could be involved in HFD-induced hypothalamic inflammation. We placed heterozygous Tgfb1-knockout (Tgfb1 +/− ) mice and wild-type (WT) littermate controls on an HFD feeding regimen (versus both on a normal-chow diet as a further control) for 3 weeks. We found that hypothalamic Tgfb1 mRNA levels in the normal chow-fed Tgfb1 +/− . Two-tailed Student's t-test was used for comparisons between two groups, and two-way analysis of variance was used for comparisons between multiple groups. *P < 0.05, **P < 0.01; n = 4 (b) and n = 8 for TGF-β1-treated WT group, n = 8 for vehicle-treated WT group, n = 9 for TGF-β1-treated Tlr4 −/− group and n = 10 for vehicle-treated Tlr4 −/− group (c,d). Error bars reflect mean ± s.e.m. npg mice were ~50% lower compared to that in normal chow-fed WT mice (Fig. 4b) . The reduction in Tgfb1 in our Tgfb1 +/− mice was comparable to that observed with a similar mouse model in a different study 35 . Under 3-week HFD feeding, hypothalamic Tgfb1 mRNA levels were significantly higher in WT mice versus the levels in WT mice on a normal chow diet, and in HFD-fed Tgfb1 +/− mice the fold difference versus Tgfb1 +/− mice on a normal chow diet was similar, indicating the heterozygous knockout mice respond similarly to WT mice with regard to hypothalamic Tgfb1 mRNA induction in response to an HFD (Fig. 4b) . However, the absolute levels of hypothalamic Tgfb1 mRNA in the heterozygous mutant mice on an HFD were similar to those in the WT mice on a normal chow diet. Thus it is possible that in spite of the fold increase of hypothalamic Tgfb1 mRNA in the mutant mice on an HFD versus a normal chow diet, sufficient overall excess TGF-β was not achieved in the mutant on an HFD to induce hypothalamic inflammation. To determine whether this was the case, we examined the mRNA levels of a number of inflammation-related genes including tumor necrosis factor-α (Tnf), interleukin-6 (Il6), suppressor of cytokine signaling-3 (Socs3), Toll-like receptor-4 (Tlr4), protein tyrosine phosphatase-1B (Ptpn1), protein kinase C-ζ (Prkcz) and protein kinase C-ι (Prkci). Three-week HFD feeding increased hypothalamic mRNA levels of these genes in WT mice but barely increased their expression in Tgfb1 +/− mice (Fig. 4b) . Therefore, excess brain TGF-β abundance plays a role in mediating diet-induced hypothalamic inflammation, but it has to reach a certain threshold in order to do so.
Although TGF-β1 injection clearly led to activation of hypothalamic NF-κB, we noted that it did not change the phosphorylated levels of IκBα when normalized by IκBα protein levels. Thus, although kinase (for example, IκB kinase)-induced IκBα phosphorylation is a crucial rapid signaling reaction in classical inflammation, this process is not primarily critical in TGF-β1-induced hypothalamic inflammation. We also examined phosphorylation of TGF-β-activated kinase-1 (TAK1), a kinase that can mediate TGF-β-induced NF-κB activation in some immune cells, but TGF-β1 injection did not lead to hypothalamic TAK1 phosphorylation (Fig. 4a) .
All of these observations suggest that TGF-β1 modulates IκBα levels in a manner that is independent of upstream kinase signaling, leading to nonclassical activation of hypothalamic NF-κB. To further assess this notion, we asked whether the effects of excess brain TGF-β could be impaired by ablation of a signaling component, such as TLR4 or myeloid differentiation primary response gene 88 (MyD88), as such components employ kinase signaling to induce IκBα phosphorylation and thus NF-κB activation. Using a genetic model, Tlr4-knockout (Tlr4 −/− ) mice, we delivered TGF-β1 or vehicle into the hypothalamic third ventricle of these mice and WT littermates via preimplanted cannula. Vehicletreated Tlr4 −/− and WT mice had normal responses in GTTs and ITTs (Fig. 4c,d) . Of note, TGF-β1 treatment led to similar extents of glucose intolerance and insulin resistance in Tlr4 −/− and WT mice (Fig. 4c,d) . Also, using Myd88-knockout mice, we observed that the lack of MyD88 did not lead to a significant reduction in glucose tolerance or insulin sensitivity following hypothalamic third ventricle TGF-β1 delivery (data not shown). Altogether, these results suggest that excess brain TGF-β may use a mechanism that directly targets IκBα rather than upstream kinase signaling to activate hypothalamic NF-κB.
A hypothalamic RNA stress response activates NF-kB In exploring how TGF-β could activate hypothalamic NF-κB without requiring proinflammatory kinase signaling, our attention was directed to a possible role of mRNA regulation. In coping with inflammatory stress, eukaryotic cells can develop a process known as an RNA stress response, which is characterized by RNA stress granules (SGs) and processing bodies (PBs) [36] [37] [38] . In this reaction, messenger ribonuclear protein byproducts exit from polysomes and form RNA SGs at discrete cytoplasmic foci. RNA SGs primarily consist of poly(A) + mRNAs containing 48S preinitiation complexes, small ribosomal subunits, mRNA decay factor tristetraprolin, translation initiation factors such as eukaryotic translation initiation factor-4E (eIF4E), eIF4G, eIF4A and eIF4B, poly(A)-binding protein and RNA helicases [36] [37] [38] . RNA stress response can lead to the export of messenger ribonuclear proteins into the PBs, resulting in a complex that harbors an array of mRNA decay machineries that act to dispose of mRNAs from SGs or polysomes [36] [37] [38] . PBs contain nontranslating mRNAs, translation repressors, mRNA decay machineries (including 5′-3′ mRNA decay system, nonsense-mediated decay pathway and RNA-induced silencing complex) and mRNA decay factors such as tristetraprolin, eIF4E, DEAD box RNA helicase family member p54/RCK, cAMP response element-binding transcription factor, B-related factor 1 RNA polymerase III transcription initiating factor IIIB subunit, eukaryotic translation initiation factor 4E transporter and RNA-binding protein Smaug [36] [37] [38] .
In this context, we analyzed the expression levels of these RNA SG and PB genes in our mouse models and found that many of them were increased in the hypothalamus of C57BL/6 mice on a 3-month HFD feeding regimen (Supplementary Fig. 6a) . Notably, hypothalamic increases of these genes were similarly induced by an injection of TGF-β1 into the third ventricle of normal mice (Fig. 5a) . In line with these observations, we examined whether the morphology of RNA SGs could be detected in the hypothalamus of these mice. We performed immunostaining of HuR, a molecular component of RNA SGs, and found that HuR-containing aggregates were present in the perinuclear regions of hypothalamic cells in TGF-β1-injected mice but barely present in control mice (Fig. 5b) . Consistent with this, we found these morphological changes in the hypothalamus of HFD-fed mice but found almost no changes in the hypothalamus of normal chow-fed mice (Supplementary Fig. 6b ). These data suggest that RNA stress response could be causally important for the induction of obesity-associated hypothalamic inflammation.
RNA SGs and PBs can mediate the degradation of mRNAs by targeting AU-rich elements (AREs) in the 3′ untranslated region [36] [37] [38] . Our analysis of gene sequences showed that an ARE is conserved in IκBα mRNAs across species (Supplementary Fig. 7 ). This information led us to suspect that TGF-β could activate NF-κB by promoting the degradation of IκBα mRNA. Using both mouse hypothalamic GT1-7 cells (Fig. 5c) and human embryonic kidney (HEK) 293 cells (data not shown), we found that IκBα mRNA levels in these cells were notably lower following TGF-β1 treatment versus vehicle treatment. When these cells were treated with both the transcriptional inhibitor actinomycin D and TGF-β, IκBα mRNA decay was more potent compared to actinomycin D treatment alone (Fig. 5d) . These results indicated that the turnover of IκBα mRNA is fast and that TGF-β has a strong effect in promoting IκBα mRNA decay.
Consistent with the in vitro data, an intra-third-ventricle-injection of TGF-β1 was sufficient to decrease hypothalamic IκBα mRNA levels (Fig. 5e) , and as expected, this mRNA change led to hypothalamic IκBα protein loss in TGF-β1-injected mice (Fig. 4a) . To test whether TGF-β-induced IκBα mRNA decay is accountable for the glucose metabolism disorder, we designed an experiment to study whether the metabolic dysfunction caused by excess brain TGF-β could be reversed through directly increasing hypothalamic IκBα mRNA. Using an approach that we established previously 23 , we employed a lentiviral system to deliver exogenous IκBα mRNA into the mediobasal hypothalamus of normal chow-fed C57BL/6 mice, and found that this lentivirus-delivered IκBα mRNA prevented TGF-β1 injection from activating hypothalamic NF-κB (Fig. 5f) . Our metabolic analysis confirmed that this treatment attenuated the effect of TGF-β1-mediated impairment of insulin sensitivity (Fig. 5g) . Altogether, our findings suggest that a hypothalamic process consisting of TGF-β excess, RNA stress response and IκBα mRNA decay mediates the metabolic dysfunction that occurs during dietary obesity.
Aging-induced glucose intolerance and hypothalamic RNA stress Finally, we studied whether the role of hypothalamic TGF-β-directed RNA SGs and PBs also affects the development of aging-related glucose and insulin disorders. We had already observed that hypothalamic Tgfb1 mRNA levels were higher in aged mice than in young mice but were lower after caloric restriction compared with age-matched mice fed ad libitum (Supplementary Table 1) . Given these results, we analyzed the expression levels of RNA SB and PB components and found that many of these molecules were higher in the hypothalamus of aged mice compared to young mice (Fig. 6a) . Using immunostaining, we confirmed that RNA SGs were present in the hypothalamus of old mice but barely present in that of young mice (Fig. 6b) .
Given the above findings, we used Tgfb1 +/− mice to study whether the partial expression of TGF-β1 in this model could protect against aging-induced glucose intolerance and insulin resistance. In this experiment, Tgfb1 +/− mice and WT controls were maintained under normal chow feeding, and we studied metabolic physiology in young versus middle-aged mice. Our follow-up showed that normal . Two-tailed Student's t-test was used for comparisons between two groups. *P < 0.05, **P < 0.01, ***P < 0.001; n = 4 mice per group (a,b) and n = 8 mice for young WT group, n = 5 mice for middle-aged WT group, n = 8 mice for young Tgfb1 +/− group and n = 7 mice for middleaged Tgfb1 +/− group (c-f). Error bars reflect mean ± s.e.m.
npg chow-fed Tgfb1 +/− mice and WT controls had similar food intake and body weight (Fig. 6c,d) . At young ages, Tgfb1 +/− and WT mice had similar glucose levels in GTTs and ITTs (Fig. 6e,f) . Both glucose tolerance and insulin sensitivity were impaired in middle-aged WT mice compared to young WT mice; in contrast, middle-aged Tgfb1 +/− mice showed significantly better responses in GTTs and ITTs (Fig. 6e,f) . Taken together, these results suggest excess TGF-β and altered RNA metabolism represent two critical factors for the development of metabolic complications during obesity and aging.
DISCUSSION
As epidemiological and clinical evidence has shown, hyperglycemia and glucose intolerance are frequently found in brain diseases such as Alzheimer's disease [39] [40] [41] . Here, we found that both obesity and aging are associated with overproduction of TGF-β in the brain, and our pharmacological and genetic models consistently revealed that excess TGF-β in the brain leads to glucose intolerance and insulin resistance in a manner that is dissociable from obesity or aging. We found that the brain-liver axis was critical for the metabolic dysfunction mediated by excess brain TGF-β, in agreement with studies demonstrating that the hypothalamus has a regulatory role in hepatic glucose production [5] [6] [7] [8] . Conceptually, our findings are in line with the literature showing that TGF-β excess is not only seen in many brain diseases but also implicated in their pathogenesis [42] [43] [44] [45] [46] . On the other hand, we should point out that despite this relevance of excess TGF-β to disease, TGF-β has important biological functions in cell growth, differentiation and transformation, and complete absence of TGF-β is developmentally lethal 47, 48 , indicating that complete lack of TGF-β is unhealthy. With regards to the CNS, lack of brain TGF-β signaling can affect neurological development or synapse function 32,49,50 , suggesting that a normal level of brain TGF-β is biologically required and therefore neuroprotective. Therefore, we speculate that increase of TGF-β in various brain diseases may initially represent an adaptive response. For example, by inducing peripheral glucose intolerance, excess central TGF-β could increase glucose availability for the brain. As glucose is almost the exclusive fuel for the brain, an increase in glucose flux to this organ can help the brain cope with various physiological stresses. However, when such induction of glucose intolerance is chronic, it lowers the threshold of developing diabetes, leading to the T2D-prone condition. Consistent with this idea, systemic TGF-β neutralization or inhibition of its signaling in db/db mice or ob/ob mice has been shown to have effects in reducing glucose or renal disorders, but these changes were associated with obesity reduction in those studies 51, 52 ; thus, it was unclear whether TGF-β could directly cause diabetes. Herein, our findings demonstrate that excess central TGF-β results in metabolic dysfunction independent of a change in body weight, and therefore, appropriate TGF-β suppression can represent a therapeutic basis for treating patients with diabetes with or without obesity. Nevertheless, further studies are necessary to determine whether TGF-β itself or the downstream mechanism represents a viable target for treating human diabetes.
Classical NF-κB activation is induced by membrane receptoractivated kinases such as IκB kinase and TAK1. Activation of these kinases rapidly leads to IκBα phosphorylation, ubiquitination and degradation, and subsequently, NF-κB is liberated from binding to IκBα, enters the nucleus and induces gene transcription 53 . This paradigm of classical NF-κB activation requires extracellular stimuli, for example, pathogens or related molecules that activate receptors such as TLRs. As a result, activated NF-κB induces gene expression of inflammatory cytokines (for example, tumor necrosis factor-α and interleukins), which are released to induce subsequent NF-κB activation through cytokine receptor signaling. Recently, both obesity and aging were revealed to be associated with hypothalamic NF-κB activation [12] [13] [14] [18] [19] [20] [23] [24] [25] [26] [27] ; however, how hypothalamic NF-κB activation is triggered in these conditions was unclear. Here, we demonstrated that a hypothalamic RNA stress response induces IκBα mRNA decay to initiate NF-κB activation, an intracellular RNA metabolismdriven event that does not rely on receptor signaling. In the literature, it has been documented that the biological function of the RNA stress response is to provide an early intracellular defense during which RNA SGs and PBs are formed to degrade ARE-containing mRNAs [36] [37] [38] . In this study, we demonstrated that IκBα mRNA has a fast turnover rate and is sensitive to RNA SG-and RNA PB-mediated mRNA decay. TGF-β excess can trigger this process, although it remains to be studied whether there are other contributing factors and how excess TGF-β triggers the RNA stress response. Furthermore, we found that induction of NF-κB-dependent inflammatory genes by shortterm HFD feeding was suppressed by TGF-β1 inhibition, suggesting that TGF-β excess is involved in initiating obesity-related hypothalamic inflammation. The fact that hypothalamic NF-κB mediates the metabolic dysfunction caused by excess brain TGF-β provides strong support for an integrated model (Supplementary Fig. 8 ) of a centrally mediated mechanism for the development of T2D. This model involves the activation of hypothalamic NF-κB by many other factors than just excess TGF-β, likely also including endoplasmic reticulum stress, proinflammatory cytokines and other inflammatory signaling molecules (for example, c-Jun N-terminal kinase). Whereas the predicted prodiabetic effects of these factors are intertwined with obesity development, here we identified an obesity-independent mechanism to support the conclusion that hypothalamic inflammation is causally involved in diabetic development.
The overall findings in this study further elucidated the notion that the content of hypothalamic inflammation in obesity or aging has unique features, and the involvement of TGF-β reflects this point. TGF-β has often been studied for its anti-inflammatory functions 28 , but here we revealed that excess brain TGF-β activates proinflammatory NF-κB. In agreement with our finding, it has been recently noticed that TGF-β can support proinflammatory functions in the context of other inflammation-related cytokines 28, 54, 55 . Hence, in the context of the recent literature that has increasingly uncovered the role of hypothalamic inflammation in the development of phenotypes associated with the metabolic syndrome [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [56] [57] [58] [59] [60] , the findings in this work suggest that the hypothalamic inflammationrelated mechanism of these phenotypes involves molecules whose proinflammatory actions are relatively moderate. Also, given our findings here and those in the previous studies, it seems the cellular mechanism of this form of hypothalamic inflammation is driven by a cross-talk between astrocytes and neurons. Notably, recent studies have demonstrated that HFD feeding can rapidly induce hypothalamic gliosis and increase of microglia 17, 22 . Our results here show that TGF-β is produced and released predominantly from astrocytes and acts on hypothalamic neurons such as POMC neurons to induce metabolic changes. This finding further indicates that hypothalamic glia-neuron interaction is important in the regulation of metabolic physiology and pathophysiology.
METHODS
Methods and any associated references are available in the online version of the paper.
npg ONLINE METHODS
Animals. Tgfb1 flox/flox mice, Tgfbr2 flox/flox mice, Tgfb1 +/− mice, GFAP-Cre mice and Tlr4 −/− mice on C57BL/6 were obtained from The Jackson Laboratory 32, [61] [62] [63] [64] and continued to be maintained on C57BL/6. CMV-lox-stop-lox-Tgfb1 mice 30 obtained from The Jackson Laboratory were backcrossed into C57BL/6. POMCCre mice maintained on C57BL/6 were used in our previous research 20, 65 . All mice were housed in a standard, pathogen-free animal facility with 12 h/12 h light and darkness cycles, and adult male mice were used in experiments of this work. Mice were maintained on normal chow since weaning, and for some experiments involving HFD feeding, an HFD (45% kcal fat, Research Diets, Inc.) was used when mice were two to three months old. Food intake and body weight of mice were measured using a laboratory scale. GTT was performed in mice through intraperitoneal (i.p.) injection of glucose at 2 g/kg body weight. ITT was performed in mice through i.p. injection of human recombinant insulin (Nova Nordisk) at the dose of 0.7 U/kg body weight. Blood glucose levels during GTT and ITT were measured with a LifeScan blood glucose monitoring system. All procedures were approved by the Institutional Animal Care and Use Committee of Albert Einstein College of Medicine.
Brain injection. As we previously described 14, 66 , using an ultra-precise (10 µm resolution) small animal stereotactic apparatus (David Kopf Instruments), a 26-gauge guide cannula (Plastics One, Inc.) was implanted into the third ventricle of anesthetized mice at the midline coordinates of 1.8 mm posterior to bregma and 5.0 mm below the surface of skull. Intra-third-ventricular injection was carried out with a 33-gauge internal cannula (Plastics One) connected to a 5-µl Hamilton Syringe. TGF-β1 (Sigma) was dissolved in 1 µl artificial cerebrospinal fluid (aCSF) for injection. Injection of aCSF was used as vehicle control. For pharmacological treatment, mice were fasted for an overnight period and received two injections of TGF-β1 versus vehicle via preimplanted cannula, one injection at night after food was removed and the second injection in the following morning at 4 h before a metabolic test such as GTT or ITT. Bilateral intra-MBH viral injections were directed by an ultra-precise stereotactic apparatus at coordinates of 1.5 mm posterior to bregma, 5.8 mm below the surface of skull and 0.3 mm lateral to midline, as previously described 14 . Purified lentiviruses suspended in 0.2 µl aCSF were injected over 10-min period via a 26-gauge guide cannula and a 33-gauge internal injector (Plastics One) connected to a 5-µl Hamilton Syringe and infusion pump (WPI Instruments).
Hyperinsulinemic-euglycemic clamp. Mice that were preimplanted with cannula in the third ventricle were anesthetized, and a catheter was inserted into the right jugular vein and crossed over from the underneath and out the back of the neck. Following surgical recovery, overnight-fasted mice were injected with TGF-β1 (4 ng) versus vehicle, once at the beginning of fasting and again the following morning at four hours before clamp. Conscious mice were then subjected to euglycemic clamp, with the blood glucose concentrations maintained at 120-130 mg/dl for four hours, followed by steady-state human insulin infusion (4 mU kg −1 min −1 ) together with infusion of 20% glucose at variable rates to maintain euglycemia. During the final 1 h of the clamp, [3-3 H]glucose and 2-deoxy-d-[1-14 C]glucose (PerkinElmer) infusions were used. Blood samples were collected from tail vein. At the end of the procedure, mice were euthanized, and various tissues were removed and quickly frozen in liquid nitrogen. Plasma insulin and glucagon concentrations were analyzed with ELISA kits (Crystal Chem. and R&D Systems).
Lentiviruses and histology. Lentiviral IκBα was cloned by inserting cDNA of dominant-negative IκBα in synapsin promoter-driven lentiviral vector as previously described 14 , and replacement of IκBα by GFP cDNA was used as the matched control. Lentiviruses were generated in HEK 293T cells and then purified as previously described 14 . Brain histology was analyzed using brain sections and immunostaining. Mice under anesthesia were transcardially perfused with 4% PFA and brains were removed, post-fixed in 4% PFA for four hours and infiltrated with 20-30% sucrose. 20-µm-thick brain sections were blocked with serum of appropriate species, penetrated with 0.2% Triton-X 100, treated with primary antibodies including mouse anti-GFAP (Millipore, MAB3402, 1:1,000), mouse anti-NeuN (Millipore, MAB377, 1:1,000), rabbit anti-TGF-β (Abcam, ab53169, 1:200) and mouse anti-HuR (Santa Cruz, sc5261, 1:500) and subsequently reacted with fluorescent secondary antibodies (Invitrogen, 1:1,000). Naive IgGs of appropriate species were used as negative controls. DAPI staining was used to reveal all cells in the section. Images were taken using a confocal microscope.
Protein, mRNA and peptide analyses. Hypothalami were isolated as previously described 14 . Tissue lysis, SDS-PAGE and western blotting were performed as previously described 19 . Primary antibodies in western blots included anti-IκBα (Santa Cruz, #SC847, 1:500), anti-p-TAK1 (Cell Signaling, #4531, 1:1,000), anti-p-IκBα (Cell Signaling, #2859, 1:1,000), anti-RelA (Cell Signaling, #3039, 1:1,000), anti-p-RelA (Cell Signaling, #4764, 1:1,000) and anti-β-actin (Cell Signaling, #4967S, 1:1,000), and secondary antibodies were HRP-conjugated anti-rabbit or goat antibody (Pierce, 1:2,000). Quantification of western blots was processed with ImageJ. Total RNA was extracted from hypothalamic tissue using TRIzol (Invitrogen), and cDNA was synthesized using M-MLV RT System (Promega). Using SYBR Green PCR Master Mix (Applied Biosystems), expression levels of target genes were analyzed via PCR amplification and quantification. GAPDH or TBP mRNA levels were used for normalization. For CSF collection and TGF-β measurement, an anesthetized mouse was placed onto the stereotactic apparatus with the head forming an angle of about 135° with the body, and then a sagittal incision in the neck skin was made inferior to the occiput, followed by penetrating a capillary tube through the dura mater into the cisterna magna to draw the CSF. Serum and CSF TGF-β content were measured using TGF-β ELISA kit (R&D Systems).
Cell culture. GT1-7 cells were cultured as described previously 14 . Briefly, GT1-7 cells were maintained in Dulbecco's Modified Eagle's Medium (Invitrogen) with 10% FBS (Hyclone) and penicillin-streptomycin (Invitrogen) at 37 °C in a humidified atmosphere containing 5% CO 2 . Cells were fasted in serum-free medium for an overnight period and then were subjected to TGF-β1 treatment at the indicated dose and time course.
Statistical analyses. Two-tailed Student's t-test was used for comparisons between two groups, and ANOVA and appropriate post hoc analyses were used for comparisons among more than two groups. Data presented met normal distribution, and statistical tests for each figure were justified appropriate. Sample sizes were chosen with adequate power based on the literature. Randomization was used in animal experiments whenever possible, but the investigators were often not blinded to allocation during experiments and outcome assessment. Data were presented as mean ± s.e.m. P < 0.05 was considered statistically significant.
